Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2012
Business WirePress Release: Alkermes plc – Thu, May 10, 2012 4:00 PM EDT
DUBLIN--(BUSINESS WIRE)--
Alkermes plc (NASDAQ: ALKS - News) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, May 17, 2012, to discuss the company’s financial results for its fiscal year ended March 31, 2012. Management will also provide financial expectations for fiscal year 2013.
The conference call will be webcast on the Investors section of Alkermes’ website at www.alkermes.com or may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988.
A replay of the conference call will be available from 11:30 a.m. EDT (4:30 p.m. BST) on Thursday, May 17, 2012, through 5:00 p.m. EDT (10:00 p.m. BST) on Thursday, May 24, 2012, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.
Business WirePress Release: Alkermes plc – Thu, May 10, 2012 4:00 PM EDT
DUBLIN--(BUSINESS WIRE)--
Alkermes plc (NASDAQ: ALKS - News) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, May 17, 2012, to discuss the company’s financial results for its fiscal year ended March 31, 2012. Management will also provide financial expectations for fiscal year 2013.
The conference call will be webcast on the Investors section of Alkermes’ website at www.alkermes.com or may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988.
A replay of the conference call will be available from 11:30 a.m. EDT (4:30 p.m. BST) on Thursday, May 17, 2012, through 5:00 p.m. EDT (10:00 p.m. BST) on Thursday, May 24, 2012, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.
Recent ALKS News
- Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting • Business Wire • 05/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:08:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:04:37 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 05/22/2026 11:59:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:59:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:57:44 PM
- Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences • Business Wire • 05/21/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:10:47 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2026 09:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:07:58 AM
- Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia • Business Wire • 05/12/2026 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:05:17 AM
- Alkermes plc Reports First Quarter 2026 Financial Results • Business Wire • 05/05/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 08:30:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2026 01:05:20 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/01/2026 08:51:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:22:08 PM
- Alkermes to Report First Quarter Financial Results on May 5, 2026 • Business Wire • 04/21/2026 08:05:00 PM
- Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting • Business Wire • 04/16/2026 11:00:00 AM
- Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry • Business Wire • 04/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:56:39 PM

